OUR MISSION IS TO IMPROVE THE RESEARCH AND DIAGNOSTIC ARSENAL OF THE GLOBAL CANCER CARE COMMUNITY AND REDUCE THE BURDEN ON THE PATIENTS AND THEIR FAMILIES


Global health systems are facing direct and indirect consequences of the rising number of the population, elderly and cancerous patients. Cancer-care upfront treatment and late-stage disease therapy costs, containment of side effects, and rehabilitation expenses will increase. Epigenetic data-driven solutions are likely to become one of the most precise and sustainable approaches to establishing the future standards of precision health care. We are open to share our technology with academic and industrial customers who are engaged in precision solutions, especially in the field of cancer risk prevention and anti-cancerous drug- or therapeutic product development actions.

Methylex solution IS game-changing in tumor profiling


Our solution is unique combination of molecular epigenetic data processing technique and bigdata-driven computational tool. It is designed to confirm clinical evidence on a large number of high-quality input data in a short period of time. Increased academic interest towards our solution is stimulating investments and driving industrialization. This can accelerate various biomedical investigations that shorten the time to market towards commercialization for effective diagnostic tests, anti-cancerous medicines, and therapeutic devices. If you would like to know more about our solution please contant us.

SUPPORTING academiC AND INDUSTRIAL CUSTOMERS TO ACHIEVE THEIR specific r&d&i GOALS


Precise analysis of drug and therapeutic response at a short timeframe

Fastlane towards cancer risk prevention

Evaluate cancer-related methylome data from raw fastQ files based on customer requirements

Implementing epigenetic data-driven R&D&I workflows in customer premises

Discover our services